Research Study

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis
Principal Investigator 
Nasreen Khalil

Overview

Body Locations and Systems 
Pulmonary Fibrosis
ClinicalTrials.gov# 
NCT03733444
Status 
Recruiting
Study Start/End 
Jun 5, 2019 to Dec 31, 2021
Locations 
Diamond Health Care Centre
Name/Title 
Marion Santos, Research Coordinator
Phone 
604-875-5091
Email Address 
marion.santos@vch.ca
Purpose of Study 

The purpose of this study is to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general.

Eligibility 

Visit ClincalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.